Trial Profile

A First-in-Human, Open-Label, Multi-Center Phase 1 Study of TST003 in Subjects With Locally Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TST 003 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Transcenta Holding

Most Recent Events

18 Oct 2024 Status changed from recruiting to active, no longer recruiting.
10 Apr 2024 Trial design presented at the 115th Annual Meeting of the American Association for Cancer Research.
23 Mar 2023 According to a Transcenta Holding media release, company announced the successful dosing of first patient in the U.S.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com